EGRIFTA® is a registered trademark of Theratechnologies Inc.
© 2014 Theratechnologies, Inc. All rights reserved.

Register here to get information about EGRIFTA® (tesamorelin for injection). Plus, find out how to start a conversation with your healthcare provider, and get access to a Patient Support Specialist to help with any questions you may have. Don't forget to provide your phone number so that we can call to see if you're eligible to save up to $500 monthly.

    •  
    •  
    •  
    •  
    •    
    •    
    • You could save up to $500
      monthly, but first, we need
      to call you and determine if
      you're eligible.

      x
         
    •    
    •  

*Required Field

As part of our commitment to patients, Theratechnologies will respect the confidentiality and privacy of your personal and medical information. Theratechnologies will only use your personally identifiable information, pursuant to our privacy policy, to:

  • Provide you with information relating to Theratechnologies' products that you may find useful
  • Contact you in the future for follow-up or market research purposes
  • Conduct internal analyses of its services

Theratechnologies may contract with third parties under our control to provide the information listed above. Do not authorize Theratechnologies to contact you if you do not want Theratechnologies to share your personally identifiable information with third parties under our control. Theratechnologies will not provide, sell or share personally identifiable information to third parties who are not under the direction of Theratechnologies without your separate consent.


 

To learn more about how we will use your personally identifiable information, please read our privacy policy.




Important Risk Information and Indication for EGRIFTA®
What is EGRIFTA®?
  • EGRIFTA ® is an injectable prescription medicine to reduce the excess in abdominal fat in HIV-infected patients with lipodystrophy. EGRIFTA ® contains a growth hormone-releasing factor (GRF).
  • The impact and safety of EGRIFTA ® on cardiovascular health has not been studied.
  • EGRIFTA ® is not indicated for weight loss management.
  • It is not known whether taking EGRIFTA ® helps improve compliance with anti-retroviral medications.
  • It is not known if EGRIFTA ® is safe and effective in children. EGRIFTA ® is not recommended to be used in children.
Who should not use EGRIFTA®?

Do not use EGRIFTA ® if you:

  • have pituitary gland tumor, pituitary gland surgery or other problems related to your pituitary gland
  • have active cancer (either newly diagnosed or recurrent) or are receiving treatment for cancer.
  • are allergic to tesamorelin or any of the ingredients in EGRIFTA®. See the end of this leaflet for a complete list of ingredients in EGRIFTA®
  • are pregnant or become pregnant. If you become pregnant, stop using EGRIFTA® and talk with your healthcare provider. See “What should I tell my healthcare provider before using EGRIFTA®?”
Who should not use EGRIFTA®?
  • have or have had cancer
  • have diabetes
  • are breastfeeding or plan to breastfeed. It is not known if EGRIFTA® passes into your breast milk. The Centers for Disease Control and Prevention (CDC) recommends that HIV-infected mothers not breastfeed to avoid the risk of passing HIV infection to your baby. Talk with your healthcare provider about the best way to feed your baby if you are taking EGRIFTA®
  • have kidney or liver problems
  • have any other medical condition.

Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. EGRIFTA® may affect the way other medicines work, and other medicines may affect how EGRIFTA® works.

How should I use EGRIFTA®?
  • Read the detailed "Instructions for Use" that comes with EGRIFTA® before you start using EGRIFTA®. Your healthcare provider will show you how to inject EGRIFTA®.
  • Use EGRIFTA® exactly as prescribed by your healthcare provider.
  • Inject EGRIFTA® under the skin (subcutaneously) of your stomach area (abdomen).
  • Change (rotate) the injection site on your stomach area (abdomen) with each dose. Do not inject EGRIFTA® into scar tissue, bruises or your navel.
  • Do not share needles or syringes with other people. Sharing of needles can result in the transmission of infectious diseases, such as HIV.
What are the possible side effects of EGRIFTA®? EGRIFTA® may cause serious side effects including:
  • Serious allergic reaction. Some people taking EGRIFTA® may have an allergic reaction.

    Stop using EGRIFTA® and get emergency help right away if you have any of the following symptoms:
    • a rash over your body
    • hives
    • swelling of your face or throat
    • shortness of breath or trouble breathing
    • fast heartbeat
    • feeling of faintness or fainting
  • Swelling (fluid retention). EGRIFTA® can cause swelling in some parts of your body. Call your healthcare provider if you have an increase in joint pain, or pain or numbness in your hands or wrist (carpal tunnel syndrome).
  • Increase in glucose (blood sugar) intolerance and diabetes. Your healthcare provider will measure your blood sugar periodically.
  • Injection site reactions. Change (rotate) your injection site to help lower your risk for injection site reactions. Call your healthcare provider for medical advice if you have the following symptoms around the area of the injection site:
    • redness
    • itching
    • pain
    • irritation
    • bleeding
    • rash
    • swelling
The most common side effects of EGRIFTA® include:
  • joint pain
  • pain in legs and arms
  • swelling in your legs
  • muscle soreness
  • tingling, numbness and pricking
  • nausea
  • vomiting
  • rash
  • itching

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of EGRIFTA®. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. To report side effects, contact Theratechnologies toll-free at 1-800-283-8088 ext. 5563. You may report side effects to FDA at 1-800-FDA-1088.

How do I store EGRIFTA®?
  • EGRIFTA® has two boxes dispensed by the pharmacy:
    • Store the Medication Box of EGRIFTA® vials in the refrigerator between 2°C and 8°C (36°F and 46°F) until the expiration date, or at or below 25°C (77°F) for 3 months or until the expiration date, whichever occurs first.
    • Store the box of Sterile Water for Injection, syringes and needles at room temperature between 20ºC to 25ºC (68°F to 77°F).
  • Keep EGRIFTA® vials in Medication Box away from light.
  • Do not freeze
  • Do not use EGRIFTA® after the expiration date printed on the carton and vial labels.
  • After mixing, use EGRIFTA® right away and throw away any unused EGRIFTA®. Do not store mixed EGRIFTA®. Also, throw away the used bottle of Sterile Water for Injection.
Keep EGRIFTA® and all medicines out of the reach of children.

General information about the safe and effective use of EGRIFTA®

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use EGRIFTA® for a condition for which it was not prescribed. Do not give EGRIFTA® to other people, even if they have the same symptoms you have. It may harm them.

Do not share your EGRIFTA® syringe with another person, even if the needle is changed. Do not share your EGRIFTA® needles with another person.